2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeuticsnews2022-04-27T13:41:43+00:00April 27th, 2022|FierceBiotech|
Cytovia inks SPAC merger to get natural killer cells prospects into the clinicnews2022-04-27T13:21:37+00:00April 27th, 2022|FierceBiotech|
Spying synthetic lethal promise, Pfizer bets $25M on Zentalis, will support cancer trialsnews2022-04-27T11:46:26+00:00April 27th, 2022|FierceBiotech|
Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapynews2022-04-27T11:12:09+00:00April 27th, 2022|FierceBiotech|
Amgen opts to DARP-out after seeing early data from $50M Molecular Partners collabnews2022-04-26T20:45:44+00:00April 26th, 2022|FierceBiotech|
UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collabnews2022-04-26T20:45:44+00:00April 26th, 2022|FierceBiotech|
Editas sees clinical promise with new FDA pediatric disease tag for another blood disordernews2022-04-26T15:03:12+00:00April 26th, 2022|FierceBiotech|
Pfizer-Valneva’s Lyme disease vaccine performs even better in childrennews2022-04-26T14:27:59+00:00April 26th, 2022|FierceBiotech|
After phase 2 flop, BerGenBio posts new data on COVID-19 prospectnews2022-04-26T12:25:22+00:00April 26th, 2022|FierceBiotech|
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitisnews2022-04-26T09:43:49+00:00April 26th, 2022|FierceBiotech|
